Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/15198
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BUYSE, Marc | - |
dc.contributor.author | Michiels, Stefan | - |
dc.date.accessioned | 2013-06-05T11:46:23Z | - |
dc.date.available | 2013-06-05T11:46:23Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | CURRENT OPINION IN ONCOLOGY, 25 (3), p. 289-295 | - |
dc.identifier.issn | 1040-8746 | - |
dc.identifier.uri | http://hdl.handle.net/1942/15198 | - |
dc.description.abstract | Purpose of review The derivation of signatures using -omics technologies is increasingly integrated in the design of clinical trials in oncology. In this review, we investigate the clinical trial designs for the validation of prognostic and predictive signatures. Recent findings Using real-life breast cancer trial examples, we highlight the pros and cons of clinical utility designs for prognostic signatures. For predictive signatures, we first review alternative procedures to test the effect of treatment in the overall population as well as in the signature-positive or signature-negative subgroup. We proceed to show why the recent literature on signature-based strategy designs discourages the use of this design. We conclude by discussing adaptive signature designs to identify and validate a signature in a single trial using cross-validation techniques. Summary Use of -omics technologies should not be an add-on to clinical trials, it must become an integral part of their design. | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject.other | clinical trials; genomics; predictive biomarker; prognostic biomarker; signature | - |
dc.subject.other | Oncology; clinical trials; genomics; predictive biomarker; prognostic biomarker; signature | - |
dc.title | Omics-based clinical trial designs | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 295 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 289 | - |
dc.identifier.volume | 25 | - |
local.format.pages | 7 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Buyse, M (reprint author) Int Inst Drug Dev, B-1340 Louvain, Belgium. Hasselt Univ, Interuniv Inst Biostat, Hasselt, Belgium. Inst Gustave Roussy, Dept Biostat & Epidemiol, Paris, France. marc.buyse@iddi.com | - |
local.publisher.place | PHILADELPHIA | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
dc.identifier.doi | 10.1097/CCO.0b013e32835ff2fe | - |
dc.identifier.isi | 000317114300012 | - |
item.accessRights | Closed Access | - |
item.fulltext | No Fulltext | - |
item.contributor | BUYSE, Marc | - |
item.contributor | Michiels, Stefan | - |
item.validation | ecoom 2014 | - |
item.fullcitation | BUYSE, Marc & Michiels, Stefan (2013) Omics-based clinical trial designs. In: CURRENT OPINION IN ONCOLOGY, 25 (3), p. 289-295. | - |
crisitem.journal.issn | 1040-8746 | - |
crisitem.journal.eissn | 1531-703X | - |
Appears in Collections: | Research publications |
SCOPUSTM
Citations
14
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
14
checked on Sep 20, 2024
Page view(s)
88
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.